Related Experiment Videos
A novel p53 mutant retained functional activity in lung carcinomas
Jiunn-Liang Ko1, Ming-Chiang Chiao, Shu-Lin Chang
1Institute of Toxicology, Chung Shan Medical University, Taichung, Taiwan, ROC. jlko@csmu.edu.tw
DNA Repair
|January 2, 2003
Summary
Mutant p53 (tumor suppressor) function was studied in lung cancer. Some mutants, like S240R, retained activity, suggesting functional p53, not just mutations, impacts prognosis.
Area of Science:
- Molecular Biology
- Cancer Genetics
Background:
- The p53 gene is a crucial tumor suppressor regulating cell growth and division.
- mdm2 is a downstream target gene transcriptionally activated by p53.
- Understanding mutant p53's role in tumorigenesis is vital for cancer research.
Purpose of the Study:
- To investigate the biological function of various p53 mutants in tumorigenesis.
- To assess the transactivation capabilities of p53 mutants on target genes mdm2, bax, and p21waf.
Main Methods:
- Site-directed mutagenesis was used to create p53 mutants (H179Y, L194R, S240R, R249S, A276D, E286Q).
- Transactivation assays were performed using co-transfection into the p53-null H1299 cell line with reporter constructs (pGL-3-mdm2, pGL-3-bax, pGL-3-p21waf).
Main Results:
- Mutant p53 S240R and E286Q showed enhanced transactivation of mdm2 (43.2% and 28.2% of wild-type, respectively).
- Mutant p53 S240R demonstrated significant growth suppression in H1299 cells, comparable to wild-type p53.
- Four other p53 mutants exhibited minimal transactivation activity, similar to the negative control.
Conclusions:
- Mutant p53 alone is not a sufficient indicator of poor prognosis in lung cancer.
- The functional status of p53, rather than just its mutation, may significantly influence lung cancer prognosis.